Analysis of the development trajectory and influencing factors of demoralization syndrome in young and middle-aged patients with lung cancer during chemotherapy

  • Yaqi Jin Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang 330000, China
  • Qi Song Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330000, China
  • Min Zhong Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang 330000, China
  • Ying Cao Department of Nursing, The First Affiliated Hospital of Nanchang University, Nanchang 330000, China
  • Yunxia Xie Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang 330000, China
  • Fan Yang Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang 330000, China
  • Xinghe Liao Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Yang Yang Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang 330000, China
Article ID: 4367
0 Views
DOI: https://doi.org/10.18282/po4367
Keywords: lung cancer; chemotherapy; disorientation syndrome; symptom burden; influencing factors; latent growth mixture modeling

Abstract

Objective: This study aims to investigate the developmental trajectories and influencing factors of demoralization syndrome in young and middle-aged patients with lung cancer. Methods: From January to December 2024, 125 young and middle-aged patients with lung cancer from a tertiary Grade A hospital in Jiangxi Province were selected via convenience sampling. Data collection included the General Information Questionnaire, Demoralization Scale-II (DS-II), MD Anderson Symptom Inventory (MDASI), and Hospital Anxiety and Depression Scale (HADS). Demoralization syndrome levels were assessed at four time points: prior to the first chemotherapy, after the second chemotherapy, after the fourth chemotherapy, and after the sixth chemotherapy. Latent growth mixture modeling (LGMM) was employed to identify demoralization syndrome trajectories, while multivariate logistic regression analysis determined the factors influencing these trajectories during chemotherapy. Results: Three distinct trajectories were identified: high demoralization with fluctuating increase (27.8%), moderate demoralization with slow increase (40.3%), and low demoralization with continuous increase (36.7%). Multivariate logistic regression revealed that patient age, symptom burden, and levels of anxiety and depression significantly influenced the developmental trajectories of demoralization syndrome in these patients (P < 0.05). Conclusion: Demoralization syndrome levels in young and middle-aged patients with lung cancer undergoing chemotherapy exhibit considerable heterogeneity. Healthcare professionals should monitor variations in demoralization syndrome across patient groups and implement targeted interventions based on the identified influencing factors to mitigate demoralization.

Published
2025-08-14
How to Cite
Jin, Y., Song, Q., Zhong, M., Cao, Y., Xie, Y., Yang, F., Liao, X., & Yang, Y. (2025). Analysis of the development trajectory and influencing factors of demoralization syndrome in young and middle-aged patients with lung cancer during chemotherapy. Psycho-Oncologie, 19(3), 4367. https://doi.org/10.18282/po4367
Issue
Vol. 19 No. 3 (2025)
Section
Article

Copyright (c) 2025 Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

1. Hung HC, Chen HW, Chang YF, et al. Evaluation of the reliability and validity of the mandarin version of demoralization scale for cancer patients. Journal of Internal Medicine of Taiwan. 2010.

2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024; 74(3): 229-263. doi: 10.3322/caac.21834

3. Feng Y, Tang F, Zhang L, et al. Effects of positive thinking nursing combined with refined nursing on psychological status and self-efficacy of young and middle-aged lung cancer patients. China Modern Physician. 2022.

4. Samurai B, Jia T. Analysis of the current status and influencing factors of alienation in young and middle-aged lung cancer patients. Evidence-based nursing; 2022.

5. Liang Z, Liu M, Zhang L, et al. Analysis of incidence trends and age changes of lung cancer in selected regions of the world. China Tumor. 2022.

6. Zane L, Sharma V, Misteli T. Common features of chromatin in aging and cancer: cause or coincidence? Trends in Cell Biology. 2014; 24(11): 686-694. doi: 10.1016/j.tcb.2014.07.001

7. Liu H, Zhang X. Comparative analysis of clinical characteristics of elderly lung cancer patients and young lung cancer patients. Chinese Journal of Modern Medicine. 2015.

8. Kobayashi M, Kako J, Kajiwara K, et al. Regarding: Humayra Rashid et al. (2020) Returning to work in lung cancer survivors—a multi-center cross-sectional study in Germany. Supp Care Cancer; Published 19 November 2020. Supportive Care in Cancer. 2021; 29(8): 4183-4184. doi: 10.1007/s00520-021-06007-0

9. Yang ZY, Lai CH, Ho CL, et al. Epidemiological Study of Return to Work and Mortality in Lung Cancer Survivors. International Journal of Environmental Research and Public Health. 2021; 19(1): 309. doi: 10.3390/ijerph19010309

10. Xiao J, Peng Y, Li Y, et al. Exploring the symptoms and psychological experiences among lung cancer convalescence patients after radical lobectomy: A qualitative study. Cancer Med. 2024.

11. Grassi L, Costantini A, Kissane D, et al. The factor structure and use of the Demoralization Scale(DS‐IT) in Italian cancer patients. Psycho-Oncology. 2017; 26(11): 1965-1971. doi: 10.1002/pon.4413

12. Wu WJ, Quan M man, Gao L, et al. Demoralization and depression in Chinese cancer patients. Supportive Care in Cancer. 2021; 29(11): 6211-6216. doi: 10.1007/s00520-021-06195-9

13. Vehling S, Kissane DW, Lo C, et al. The association of demoralization with mental disorders and suicidal ideation in patients with cancer. Cancer. 2017; 123(17): 3394-3401. doi: 10.1002/cncr.30749

14. An E, Lo C, Hales S, et al. Demoralization and death anxiety in advanced cancer. Psycho-Oncology. 2018; 27(11): 2566-2572. doi: 10.1002/pon.4843

15. Ni P, Chen JL, Liu N. Sample size estimation for quantitative studies in nursing research. Chinese Journal of Nursing. 2010.

16. Robinson S, Kissane DW, Brooker J, et al. Refinement and revalidation of the demoralization scale: The DS‐II—internal validity. Cancer. 2016; 122(14): 2251-2259. doi: 10.1002/cncr.30015

17. Ou N, Qi S, Hu X, et al. Analysis of the current status and influencing factors of loss of will syndrome in cancer patients. Journal of Nursing. 2021.

18. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000.

19. Wang XS, Wang Y, Guo H, et al. Chinese version of the M. D. Anderson Symptom Inventory. Cancer. 2004; 101(8): 1890-1901. doi: 10.1002/cncr.20448

20. Wondie Y, Mehnert A, Hinz A. The Hospital Anxiety and Depression Scale (HADS) applied to Ethiopian cancer patients. PLOS ONE. 2020; 15(12): e0243357. doi: 10.1371/journal.pone.0243357

21. Jörnsten R, Keleş S. Mixture models with multiple levels, with application to the analysis of multifactor gene expression data. Biostatistics. 2008.

22. Guo Q. Factors influencing negative emotions during chemotherapy and intervention countermeasures for gastric cancer patients. Inner Mongolia University; 2024.

23. Wu F, Lai Q, Qin T, et al. Progress of research on the application of narrative nursing in lung cancer patients with loss of ambition. Contemporary Nurses. 2022.

24. Shao L, Fang X, Wang D, et al. Analysis of the trajectory of physical activity changes and influencing factors during chemotherapy in breast cancer patients. Journal of Nursing. 2025.

25. Xiao T, Han S, Li Q, et al. The mediating effect of positive coping in the association between inner strength and demoralization in lung cancer chemotherapy patients. Supportive Care in Cancer. 2025; 33(3). doi: 10.1007/s00520-025-09185-3

26. Zhao J, Yu X, Deng T. A study of the relationship between depression and anxiety and symptom burden in advanced cancer patients. Journal of Xinjiang Medical University. 2020.

27. Morrison EJ, Novotny PJ, Sloan JA, et al. Emotional Problems, Quality of Life, and Symptom Burden in Patients with Lung Cancer. Clinical Lung Cancer. 2017; 18(5): 497-503. doi: 10.1016/j.cllc.2017.02.008

28. Yang X, Zhou H, Wang L, et al. Meta-analysis of factors affecting loss of will syndrome in cancer patients. Nursing Practice and Research. 2023.

29. Xu M, Lin W, Ning L, et al. Potential profiling of self-management behaviors in lung cancer patients. Chinese Journal of Nursing. 2024.

30. Tang PL, Wang HH, Chou FH. A Systematic Review and Meta-Analysis of Demoralization and Depression in Patients with Cancer. Psychosomatics. 2015; 56(6): 634-643. doi: 10.1016/j.psym.2015.06.005

31. Ignatius J, De La Garza R. Frequency of demoralization and depression in cancer patients. General Hospital Psychiatry. 2019; 60: 137-140. doi: 10.1016/j.genhosppsych.2019.04.013